GSK PLC Sponsored ADR (NYSE:GSK) Receives $53.00 Average PT from Analysts

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have been assigned an average rating of “Reduce” from the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $53.00.

GSK has been the topic of several analyst reports. Wall Street Zen lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 7th. Weiss Ratings upgraded shares of GSK from a “hold (c+)” rating to a “buy (b)” rating in a report on Friday, May 1st. TD Cowen reiterated a “hold” rating on shares of GSK in a report on Monday, February 9th. Citigroup reiterated a “neutral” rating on shares of GSK in a report on Monday, February 9th. Finally, Barclays reiterated an “underweight” rating on shares of GSK in a report on Friday, February 20th.

Hedge Funds Weigh In On GSK

Institutional investors and hedge funds have recently modified their holdings of the stock. Fisher Asset Management LLC grew its stake in shares of GSK by 2.8% in the third quarter. Fisher Asset Management LLC now owns 32,227,615 shares of the pharmaceutical company’s stock valued at $1,390,944,000 after acquiring an additional 889,210 shares in the last quarter. Brighton Jones LLC acquired a new position in shares of GSK in the fourth quarter valued at about $528,000. Farther Finance Advisors LLC grew its stake in shares of GSK by 146.6% in the fourth quarter. Farther Finance Advisors LLC now owns 29,529 shares of the pharmaceutical company’s stock valued at $1,448,000 after acquiring an additional 17,553 shares in the last quarter. Prime Capital Investment Advisors LLC grew its stake in shares of GSK by 182.7% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 30,188 shares of the pharmaceutical company’s stock valued at $1,480,000 after acquiring an additional 19,509 shares in the last quarter. Finally, PFA Pension Forsikringsaktieselskab acquired a new position in shares of GSK in the fourth quarter valued at about $6,385,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Performance

NYSE GSK opened at $51.52 on Friday. The company has a current ratio of 0.79, a quick ratio of 0.52 and a debt-to-equity ratio of 0.80. The firm’s fifty day moving average price is $53.82 and its two-hundred day moving average price is $52.37. GSK has a 1 year low of $35.45 and a 1 year high of $61.69. The firm has a market capitalization of $104.54 billion, a P/E ratio of 13.39, a price-to-earnings-growth ratio of 2.63 and a beta of 0.38.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 9th. Shareholders of record on Friday, May 15th will be issued a $0.44 dividend. This represents a $1.76 annualized dividend and a dividend yield of 3.4%. The ex-dividend date is Friday, May 15th. GSK’s payout ratio is currently 47.01%.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.